A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2

  Measured over: Cycles 1 & 2 - 14 days per cycle

• Dose escalation part 1B: Presence of dose-limiting toxicities (DLTs) in Cycle 1 to 3 in part B

  Measured over: Cycle 1 to 3 -14 days per cycle

• Dose escalation and Japan Cohort F: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

  Measured over: The time from the first dose of study interventions up to 30 days after last dose of study interventions

• Dose expansion/optimization: Objective response rate (ORR)

  Measured over: From baseline to the end of dose expansion/optimization (up to 2 years)

Changes Tremor has spotted